Figure 1.
All patients. Event-free survival (A), overall survival (B) with estimates for 24 months after CAR T-cell infusion, relapse-free survival (C), CIR (D), NRM (E), and duration of B-cell aplasia with estimates for 24 months after response.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.